The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy.
Histologic changes indicative of gastroesophageal reflux disease (GERD) are found on both sides of the squamocolumnar junction (Z-line). In the gastric cardia, inflammation is found as part of GERD in the absence of Helicobacter pylori or other causes of gastritis (carditis). The squamous mucosa is the location most likely to show inflammatory changes, such as neutrophils or eosinophils, close to the Z-line, whereas traditional reactive changes in the squamous mucosa are found only in biopsies taken at least 3 cm above the Z-line. Endoscopic criteria for GERD have a morphologic counterpart in capillary congestion and hemorrhage into the papillae, which have largely been ignored by pathologists as secondary to biopsy trauma. A biopsy protocol that maximizes the chances of detecting changes of GERD is suggested. The traditional definition of Barrett's esophagus as requiring 3 cm of glandular mucosa extending into the esophagus is no longer tenable. However, even the concept of short-segment Barrett's esophagus, in which less than 3 cm of intestinalized mucosa is present, often as tongues, is being challenged because random biopsies immediately distal to the Z-line may also show intestinal metaplasia when Barrett's esophagus is unsuspected endoscopically. Moreover, it is difficult or impossible to determine whether these changes indicate the earliest lesion of Barrett's esophagus or intestinal metaplasia in native cardiac mucosa. It is suggested that Barrett's esophagus be redefined as intestinal metaplasia in the lower esophagus. It is presently unclear whether patients with such minimal Barrett's epithelium are at increased risk for adenocarcinoma or require surveillance. Successful therapy for GERD results in healing of disease in squamous mucosa and may result in regression of Barrett's epithelium. In the stomach it may be associated with temporary regression of H. pylori and associated inflammation, migration of H. pylori into the oxyntic mucosa, hypertrophy and hyperplasia of parietal cells, and a variant of fundic gland polyps. Some patients may be at risk for accelerated atrophic gastritis if inflammation is present before therapy.
Riddell
R H
RH
Department of Pathology, McMaster University Medical Centre, Hamilton, Ontario, Canada.
D000328:Adult; D001471:Barrett Esophagus / Q000188:drug therapy / Q000473:pathology*; D001706:Biopsy; D002648:Child; D016145:Endoscopy, Digestive System; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004804:Eosinophils / Q000473:pathology; D004947:Esophagus / Q000187:drug effects / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy / Q000473:pathology*; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007422:Intestines / Q000473:pathology; D008214:Lymphocytes / Q000473:pathology; D008679:Metaplasia; D009504:Neutrophils / Q000648:ultrastructure; D013270:Stomach / Q000187:drug effects / Q000473:pathology
D004791:Enzyme Inhibitors